Is Egrifta (Tesamorelin) Legal in Washington State?

Federal Legal Framework: Why FDA Approval Matters First

Tesamorelin's federal status determines everything that happens at the state level. Washington cannot approve or ban a drug independently of the federal Controlled Substances Act or the Federal Food, Drug, and Cosmetic Act, so the federal picture must be clear before looking at state rules.

Egrifta (tesamorelin acetate) received FDA approval on November 10, 2010 under NDA 022505 for the reduction of excess abdominal fat in HIV-infected adults with lipodystrophy. A reformulated version, Egrifta SV (2 mg/vial), received supplemental approval in 2019. FDA NDA 022505 approval history is available at the FDA Drugs@FDA database.

What FDA Approval Actually Means for Patients

FDA approval means tesamorelin is a legal prescription drug in all 50 states, including Washington. A patient cannot simply purchase it. They need a valid prescription from a licensed practitioner who has established a legitimate provider-patient relationship. That relationship may be formed in person or, in Washington, through a synchronous telehealth encounter.

Controlled Substance Status

Tesamorelin is a synthetic growth hormone-releasing factor (GRF) analog. It is not listed in any schedule of the DEA Controlled Substances Act. The DEA publishes its current scheduling list at DEA Diversion Control. Because tesamorelin is not scheduled, it does not require DEA-issued prescriber registration to prescribe, and pharmacies do not apply Schedule II-V dispensing restrictions to it. This is a meaningful practical difference from, for example, anabolic steroids (Schedule III).

Washington State Legal Framework

Washington State has no law that specifically restricts tesamorelin beyond the requirements that apply to any legend (prescription-only) drug. The relevant statutes are the Washington Pharmacy Quality Assurance Commission (PQAC) rules under RCW 18.64 and the Medical Quality Assurance Commission (MQAC) standards under RCW 18.71.

Washington Pharmacy Quality Assurance Commission (PQAC)

The PQAC licenses pharmacies, pharmacists, and pharmacy technicians operating in Washington. It adopts rules under WAC 246-869 that govern compounding, dispensing, and drug labeling. A Washington-licensed pharmacy may dispense brand-name Egrifta on a valid prescription. A 503A compounding pharmacy licensed in Washington may also compound tesamorelin under the federal 503A framework, provided the preparation meets USP Chapter 797 sterility standards for sterile compounds.

Washington Medical Quality Assurance Commission (MQAC)

MQAC governs physician prescribing. Under Washington's medical practice act, a physician may prescribe any FDA-approved drug for any indication, including off-label uses, as long as the decision is supported by adequate medical justification and documented in the patient's record. Prescribing tesamorelin off-label (for example, for age-related growth hormone deficiency or body composition in non-HIV patients) is therefore legally permissible under Washington law, though it is the prescriber's responsibility to document medical necessity.

Telehealth Parity in Washington

Washington's telehealth parity statute (RCW 74.09.325) requires insurers to cover services delivered via telemedicine at the same rate as in-person services. For patients seeking tesamorelin through a telehealth platform, a licensed Washington provider may conduct a synchronous video visit, complete the clinical evaluation, and issue a valid prescription. The prescription may then be filled at a Washington retail pharmacy or shipped from a licensed out-of-state pharmacy registered to do business in Washington.

Compounding Tesamorelin: 503A vs. 503B Rules

Compounded tesamorelin is not the same product as FDA-approved Egrifta, and the legal pathway differs meaningfully depending on which type of compounder is involved. Understanding the difference between 503A and 503B facilities is essential for both patients and prescribers.

503A Compounding Pharmacies

Section 503A of the Federal Food, Drug, and Cosmetic Act covers traditional compounding pharmacies that prepare drugs for individual patients based on a valid prescription. Under 503A, a compounder may use a bulk drug substance that appears on the FDA-approved "bulks list" (21 CFR Part 216) or that meets the criteria of a United States Pharmacopeia (USP) monograph. The FDA maintains the current 503A bulks list here.

Tesamorelin's status on that list has shifted over time. Prescribers and patients should verify the current FDA bulks-list status before ordering from a 503A compounder, because the FDA periodically adds or removes substances. A pharmacy compounding tesamorelin when it is not on the bulks list and when a commercially available FDA-approved product (Egrifta SV) exists may be operating outside the 503A safe harbor.

503B Outsourcing Facilities

Section 503B covers FDA-registered outsourcing facilities that may produce larger batches of compounded drugs without a patient-specific prescription, subject to FDA inspections and current Good Manufacturing Practice (cGMP) standards. The FDA publishes the list of registered 503B outsourcing facilities here. A 503B facility may compound tesamorelin if FDA has not determined it to be essentially a copy of Egrifta and if the facility is operating within its registration. Washington patients receiving tesamorelin from a 503B facility should confirm that the facility is on the FDA's current registered list.

The "Essentially a Copy" Problem

FDA guidance states that a compounded drug product is not permitted if it is essentially a copy of a commercially available approved drug. FDA guidance on this issue is published on the FDA compounding page. Because Egrifta SV is commercially available, a 503A compounder preparing plain 2 mg tesamorelin at the same dose for a routine patient may face regulatory scrutiny. Some compounders attempt to differentiate their formulations (for example, by adding specific excipients or using different concentrations), but prescribers should request documentation from any compounder confirming its legal basis for preparing tesamorelin.

HealthRX Clinical Framework: Verifying a Tesamorelin Compounder in Washington

Before ordering compounded tesamorelin for a Washington patient, a prescriber should confirm four things:

1. The compounder holds a current Washington PQAC license or is registered to ship into Washington.
2. The compounder is either a 503B facility on the current FDA-registered list or a 503A pharmacy dispensing on a patient-specific prescription with documented bulks-list compliance.
3. The compounded product has a current USP 797-compliant certificate of analysis from a third-party analytical lab.
4. The patient's clinical record contains a documented rationale for compounded vs. Brand-name Egrifta (e.g., cost, specific formulation need).

Clinical Basis for Prescribing Tesamorelin in Washington

Legal access is only part of the picture. A Washington prescriber deciding whether to prescribe tesamorelin needs a clinical rationale grounded in published evidence.

Evidence in HIV-Associated Lipodystrophy

The key Phase 3 trials (LIPO-010 and LIPO-011, combined N = 816) demonstrated that tesamorelin 2 mg/day produced a statistically significant reduction in visceral adipose tissue (VAT) of approximately 15 to 18% compared with placebo over 26 weeks. These trials are summarized in the prescribing information available on FDA Drugs@FDA. A published analysis in the New England Journal of Medicine reported that tesamorelin reduced VAT by a mean of 18.1% vs. 2.0% for placebo (P<0.001) at 26 weeks in HIV-positive adults. Falutz J et al., NEJM 2007;357(23):2359-2370.

IGF-1 and Growth Hormone Monitoring

Tesamorelin raises serum IGF-1. The Egrifta SV prescribing information states that IGF-1 should be checked at baseline and monitored during treatment, with dose reduction or discontinuation considered if IGF-1 rises above the age- and sex-adjusted upper limit of normal. Full prescribing information is available on FDA Drugs@FDA. Washington providers using tesamorelin off-label for growth hormone secretagogue purposes should apply the same IGF-1 monitoring standard to off-label cases.

Off-Label Use: What the Evidence Shows

Several smaller studies have examined tesamorelin in non-HIV populations. A 2014 trial published in JAMA (N = 152 older adults) found that tesamorelin 1 mg/day for 20 weeks reduced VAT by 8.5% and improved cognition scores compared with placebo. Baker LD et al., JAMA Neurol 2014;71(5):562-570. Off-label prescribing in Washington based on this kind of evidence is legal, but the prescriber carries documentation responsibility.

How to Get a Legitimate Tesamorelin Prescription in Washington

Obtaining tesamorelin legally in Washington requires a licensed prescriber, a valid clinical indication, and a licensed dispensing pharmacy. The steps below apply whether a patient uses in-person care or telehealth.

Step 1: Clinical Evaluation

A Washington-licensed MD, DO, ARNP, or PA must evaluate the patient. For the FDA-approved HIV lipodystrophy indication, documentation of HIV diagnosis, antiretroviral therapy, and measured visceral fat accumulation (typically via DXA or CT) supports the prescription. For off-label use, the prescriber should document the specific clinical rationale, reviewed labs (including baseline IGF-1, fasting glucose, and HbA1c), and patient consent to off-label therapy.

Step 2: Prescription Issuance

The prescriber writes a standard prescription for tesamorelin. Because tesamorelin is not a controlled substance, no special DEA triplicate form is required. The prescription may be transmitted electronically to any Washington-licensed pharmacy or to an out-of-state pharmacy registered to ship into Washington.

Step 3: Pharmacy Selection

Patients have three options:

• Brand-name Egrifta SV from a retail or specialty pharmacy. This is the safest legal path for the approved indication.
• 503B outsourcing facility. Appropriate when a prescriber determines that a different concentration or formulation is clinically necessary and the facility is on the current FDA-registered 503B list.
• 503A compounding pharmacy. Permissible when a patient-specific prescription exists and the compounder has documented bulks-list compliance for tesamorelin at the time of dispensing.

Step 4: Insurance and Prior Authorization

For HIV lipodystrophy, Egrifta SV may be covered under Washington Apple Health (Medicaid) or private insurance with prior authorization. Washington State Health Care Authority drug coverage policies are published at hca.wa.gov. Off-label compounded tesamorelin is almost never covered by insurance, so patients typically pay out of pocket. Manufacturer patient-assistance programs may reduce brand-name costs.

Step 5: Ongoing Monitoring

After initiation, Washington providers should schedule follow-up at 4 to 6 weeks for IGF-1 and glucose monitoring, then every 3 months. The American Association of Clinical Endocrinology (AACE) guidelines recommend that any growth hormone axis intervention include serial IGF-1 measurement, as excess IGF-1 has been associated with increased insulin resistance and theoretical oncologic risk. AACE Growth Hormone Deficiency Guidelines are available at aace.com.

Risks, Contraindications, and Washington Prescriber Liability

Legal access does not eliminate clinical risk. Washington prescribers should be familiar with tesamorelin's contraindications and document screening for each one.

Key Contraindications

The Egrifta SV prescribing information lists the following contraindications:

• Active malignancy or history of malignancy (growth hormone-releasing factor analogs may accelerate tumor growth via IGF-1)
• Pregnancy (tesamorelin is Pregnancy Category X for the HIV lipodystrophy indication)
• Hypersensitivity to tesamorelin or any excipient
• Active pituitary disease, hypothalamic disease, or prior pituitary surgery or radiation

Glucose and Diabetes Risk

Tesamorelin raises fasting glucose and insulin resistance in some patients. The package insert reports that 4.3% of tesamorelin-treated patients vs. 1.3% of placebo-treated patients developed diabetes mellitus or pre-diabetes during the Phase 3 trials. Washington providers should obtain a fasting glucose and HbA1c before initiation and monitor at every follow-up visit.

Prescriber Documentation Standards

Washington MQAC enforcement actions for off-label prescribing typically center on lack of documentation rather than on the prescribing decision itself. A prescriber who documents: (1) the clinical indication, (2) the evidence reviewed, (3) the informed consent discussion, (4) baseline labs, and (5) a monitoring plan is in a strong defensive position if a complaint is filed.

Tesamorelin vs. Other Peptides in Washington: A Comparative Note

Washington patients sometimes ask how tesamorelin compares to other growth hormone secretagogues in terms of legal status. The contrast is significant.

Sermorelin is also FDA-approved (for growth hormone deficiency diagnosis, not for body composition) and follows a similar 503A/503B compounding pathway. Ipamorelin and CJC-1295 are not FDA-approved drugs and are not on the 503A bulks list as of 2025. They are classified by the FDA as research chemicals when sold for human use outside an IND, placing them in a different and substantially riskier legal category than tesamorelin. FDA's position on unapproved peptides for human use is summarized on the FDA compounding guidance page. A Washington patient seeking a legal, clinically studied, FDA-approved growth hormone secretagogue for an appropriate clinical purpose should understand that tesamorelin occupies a different regulatory tier than most other peptides currently marketed through wellness clinics.